Answers are grounded in this paper and cite their sources.
Sir, Carbapenems are one of the most critically important antimicrobials considered as drugs of last choice in clinical settings. However, during the last few years, the prevalence of resistance to these antimicrobial agents, especially in Pseudomonas and Enterobacteriaceae, has been increasing worldwide.1–3 In Gram-negative bacteria, the mechanisms of resistance include the production of β-lactamases (carbapenemases), changes in the permeability of the membranes (i.e. loss of porins) and efflux pumps. Within the carbapenemases, the class B metallo-β-lactamases, such as VIM, IMP and NDM, play an important role because of their worldwide spread among different bacterial species, which is based on their location on mobile genetic elements.2,4,5 Currently, the national RESET project (www.reset-verbund.de) performs several longitudinal and cross-sectional studies of German farms, and potential extended spectrum β-lactamase (ESBL)-carrier organisms are collected (using MacConkey agar containing 1 mg/L cefotaxime as selective medium). All isolates sent to the Federal Institute for Risk Assessment for further analyses (n = 221) were tested for their antimicrobial susceptibility by the CLSI disc diffusion method (CLSI M2-A10 and M100-S21). They were analysed against a panel of 17 β-lactams (Oxoid, Wesel, Germany), including ampicillin (10 μg), piperacillin (100 and 30 μg), ticarcillin (75 μg), cefalotin (30 μg), cefuroxime (30 μg), ceftiofur (30 μg), ceftriaxone (30 μg), ceftazidime (30 and 10 μg), cefotaxime (30 and 5 μg), cefpodoxime (10 μg), cefepime (30 μg), cefoxitin (30 μg), aztreonam (30 μg), imipenem (10 μg), ertapenem (10 μg), meropenem (10 μg) and amoxicillin/clavulanic acid (30 μg). The 30, 10 and 5 μg amounts for piperacillin, ceftazidime and cefotaxime, respectively, are the disc concentrations recommended by EUCAST (www.eucast.org). The isolates were also tested for their susceptibility to chloramphenicol (30 μg), florfenicol (30 μg), amikacin (30 μg), gentamicin (10 μg), kanamycin (30 μg), streptomycin (10 μg), spectinomycin (100 μg), nalidixic acid (30 μg), ciprofloxacin (5 μg), tetracycline (30 μg), trimethoprim (5 μg), sulfamethoxazole (300 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg) and colistin (10 μg). The results were interpreted using both CLSI clinical breakpoints (M100-S21) and, when available, the EUCAST epidemiological cut-off values (ECOFFs), which consider isolates with an acquired or mutational resistance mechanism to the drug in question as the non-wild-type population (www.eucast.org). In all isolates, the characterization of the β-lactamase-encoding genes blaTEM, blaOXA, blaCARB, blaCTX, blaSHV, blaACC, blaCIT, blaDHA, blaEBC, blaFOX and blaMOX, additional resistance genes, and class 1 integrons was conducted as previously described.6 The phylogenetic group, and for selected isolates the multilocus sequence type (MLST; http://mlst.ucc.ie/mlst/dbs/Ecoli), was also determined. One of the Escherichia coli isolates tested, R178, showed resistance to all penicillins, cephamycins, cephalosporins and amoxicillin/clavulanic acid, but was susceptible to aztreonam. R178 also showed a zone diameter of 22 mm for imipenem (intermediate by the CLSI clinical breakpoint and non-wild-type by the EUCAST ECOFF), 24 mm for ertapenem (susceptible by the CLSI clinical breakpoint and non-wild-type by the EUCAST ECOFF) and 25 mm for meropenem (susceptible by the CLSI clinical breakpoint and non-wild-type by the EUCAST ECOFF). It was also resistant to streptomycin and sulfamethoxazole (following the CLSI clinical breakpoints; for disc diffusion, no ECOFFs available). All these resistances could be transformed to an E. coli recipient (ElectroMax DH10B, Thermo Fischer). Both R178 and the transformant, TR178, carried the AmpC β-lactamase-encoding gene blaACC-1, which confers cephalosporin and cephamycin resistance. The expression of this gene alone could not explain the zone diameter results observed for the three carbapenems, suggesting the presence of another mechanism.2,3 The positive results with the modified Hodge test, the double disc synergy test and the combined disc test using EDTA indicated the presence of a carbapenemase.1–3 Using a multiplex PCR targeting blaIMP, blaVIM and blaKPC genes and a single PCR for blaOXA-48,7 a fragment of 390 bp, which corresponded to blaVIM, was obtained. The sequence of a 748 bp blaVIM PCR fragment8 indicated the presence of blaVIM-1 (accession no. AF191564). This fact was confirmed, as described below. blaVIM genes have been found in different integrons (i.e. In31, In70, In110 and In450) and/or transposons (i.e. Tn3, Tn402 and Tn21). In fact, R178 carried a class 1 integron with a variable region of 2522 bp using the 5′CS–3′CS primers.6 Within this variable region we detected blaVIM-1,aacA4 [also labelled aac(6′)-Ib, amikacin/kanamycin resistance; not detected phenotypically in R178] and aadA1 [also labelled ant(3″)-Ia, streptomycin/spectinomycin resistance]. The integron also carried the qacEΔ1 (quaternary ammonium compound resistance) and sul1 (sulphonamide resistance) genes in the 3′ conserved region. This integron, labelled In110, had been found in other enterobacteria, such as Klebsiella and Enterobacter cloacae, as well as in Pseudomonas in different South European countries.5 The R178 integron and part of its genetic environment (5385 bp, Figure 1; accession no. HE663536) was sequenced (Eurofins MGW Operon, Ebersberg, Germany), indicating its insertion within Tn21 as previously described (accession no. GQ422826).5 The blaVIM-1 genes have been found located on IncHI2, IncN, IncI1 and IncW plasmids in different hospital settings.4,5 In fact, the R178 class 1 integron was located on pRH-R178, a ∼220 kb IncHI2 plasmid (determined by S1-PFGE analyses and a PCR-based replicon scheme),6 which also carried the blaACC-1 and strA/B (streptomycin resistance) genes. Schematic representation of a 5385 bp pRH-R178 region that contains part of the blaVIM-1 In110 integron and its genetic environment (HE663536). *intI1 sequence identical to the one shown in accession no. AM180753 (In71 integron). The triangle indicates a mutation inside the P1 promoter (−35 TTGACA; −10 TAAGCT) with respect to the sequence with accession no. GQ422826 (position 6421, G → T), corresponding to Pc hybrid 2. The white arrows indicate partial sequences. The striped arrows indicate resistance gene cassettes contained in the variable region of the integron. R178 was obtained during a longitudinal study in 2011 from a German pig farm holding 4100 pigs. The sample was taken, using gauze socks, from the corridor of a fattening unit with 5-month-old pigs. The R178 isolate was ascribed to ST88 and phylogenetic group A. Interestingly, other ST88 E. coli registered in the MLST database were obtained, among other sources, from chicken, cattle, turkeys and humans sampled in Germany as well. This is the first report on the presence of a carbapenemase-encoding gene in E. coli isolated from a livestock farm. How the isolate got there (colonized pig/environment/human) is not yet known. However, during the revision of this manuscript, we also detected blaVIM-1 in another E. coli isolated from faeces, 3months before R178, on the same farm, indicating the animal carriage of the gene, integron and plasmid (data not shown). Also recently, Acinetobacter baumannii expressing OXA-23 isolated from cattle in France was reported.9 The occurrence of ESBLs in Enterobacteriaceae (E. coli, Klebsiella and Salmonella) isolated from food-producing animals and the increase in their prevalence is a current problem worldwide,6,10 but until now the presence of carbapenemases seemed to be mainly restricted to humans. Taking into account the low expression of some carbapenemases and their affinity for different carbapenems (i.e. intermediate resistance to ertapenem, and decreased susceptibility for imipenem and meropenem) in some isolates,2,3 the prevalence of carbapenemases in bacteria from livestock can be underestimated. Their level of expression could vary in vivo,3 depending on the selective pressure (i.e. frequent use of carbapenems in hospital settings). In fact, in Germany carbapenems are not allowed for the treatment of livestock animals. The presence of carbapenemase-encoding genes located on highly effective mobile genetic elements in the livestock environment, and the possibility of their transmission via food in the community and/or hospitals is worrying and an important issue for public health. This work was supported by the Federal Institute for Risk Assessment, BfR (BfR-46-001; 45-005) and the RESET Project (FKZ01Kl1013B; BMVL, German Federal Ministry for Education and Research). None to declare. We thank B. Baumann and W. Barownick (BfR), and M. Thieck and H. Jansen (FU) for their technical support. We thank C. von Salviati and H. Laube for sampling work. We also thank F. Aarestrup, H. Hasman, R. Hendriksen and A. Carattoli for control strains, and Y. Pfeifer for her advice.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: